NCT07627737Not yet recruiting
Blood Flow Restriction Combined With Aerobic or Resistance Exercise in Heart Failure
Comparison of the Effects of Aerobic or Resistance Exercises Combined With Blood Flow Restriction on Muscle Oxygenation, Serum BNP Levels, Functional Capacity, and Quality of Life in Patients With Heart Failure
Source: ClinicalTrials.gov · Last updated 4 Jun 2026
Brief summary (registry, in English)
The aim of this study is to compare the clinical effects of aerobic and resistance exercise modalities combined with blood flow restriction in patients with stable heart failure, and to determine the most effective, feasible, and evidence-based rehabilitation approach. In individuals with heart failure, limited exercise tolerance increases the importance of training strategies that can induce high physiological adaptations with low mechanical loads. In this context, exercise interventions combined with blood flow restriction have attracted increasing attention due to their low-intensity nature and potential clinical benefits. This study is designed as a prospective, parallel-group, randomized controlled clinical trial to be conducted in 40 patients diagnosed with stable heart failure. Participants will be randomized into two groups: a blood flow restriction- combined aerobic exercise group and a blood flow restriction-combined resistance exercise group, both applied under supervision three times per week for eight weeks. All participants will be assessed before and after the intervention in terms of muscle oxygenation, serum B-type natriuretic peptide (BNP) levels, functional capacity, and quality of life. The expected outcome of this study is to obtain comparative data on the clinical effectiveness of blood flow restriction- combined exercise interventions in patients with stable heart failure and to identify which exercise modality provides superior clinical benefits. The findings are anticipated to contribute to the development of short-term, low-cost rehabilitation protocols and to provide evidence-based guidance for clinical practice.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 31 May 2026
- Start date
- Jun 2026
- Primary completion date
- Jun 2027
- Lead sponsor
- Biruni University
- Diseases
- Heart failure
- NCT number
- NCT07627737
What you commit to
- Study type: Interventional
- Planned participants: 40
- From Jun 2026 to the primary completion date, Jun 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- use of dual antiplatelet therapy or anticoagulants, including NOACs, low-molecular-weight heparin, or vitamin K antagonists.
Other illness
- history of acute coronary syndrome or revascularization within the last 12 months,
- uncontrolled hypertension, defined as ≥180/≥110 mmHg or 160-179/100--109 mmHg despite treatment, or uncontrolled arrhythmia,
- conditions contraindicating the application of blood flow restriction training, such as significant peripheral arterial disease or atherosclerosis obliterans,
- severe liver disease,
- moderate to severe valvular disease,
- angina pectoris and use of medications known to affect ischemic conditioning/occlusion, such as cyclosporine or glibenclamide,
Lab values
- impaired renal function, defined as eGFR \<30 mL/min,
Other
- severe orthopedic or neurological limitations that would prevent exercise,
- presence of atrial fibrillation or a pacemaker,
- peripheral neuropathy,
- dialysis,
- moderate to severe COPD,
- hospitalization due to cardiovascular causes within the last 30 days,
- intracranial aneurysm, arteriovenous malformation, cerebral neoplasm, or abscess,
Who the study is looking for
- NYHA functional class I-III,
- HFrEF and/or HFmrEF with left ventricular ejection fraction \<50%,
- functional capacity that does not prevent participation in exercise, and
- clinical stability within the last 3 months.
Age in the registry: 45 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Biruni University Coordinator of this site? Confirm its status | Istanbul | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.